Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

Califf, RM; Boolell, M; Haffner, SM; Bethel, MA; McMurray, J; Duggal, A; Holman, RR; NAVIGATOR, ; Study Group, (2008). Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 156(4), (2008), pp. 623-632. St. Louis, Mo.: Elsevier 10.1016/j.ahj.2008.05.017

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Diem, Peter

ISSN:

0002-8703

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:06

Last Modified:

06 Mar 2014 23:03

Publisher DOI:

10.1016/j.ahj.2008.05.017

Web of Science ID:

000259963300002

URI:

https://boris.unibe.ch/id/eprint/28735 (FactScience: 128358)

Actions (login required)

Edit item Edit item
Provide Feedback